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Background: Intimate partner violence (IPV) victimization is a prevalent issue among women residing in Mexico
City. Comprehensive and integrated health care provider (HCP) delivered programs in clinic-settings are needed, yet
few have been evaluated in Latin America, including Mexico. In addition, there has been minimal attention to
interventions among lower income women presenting at settings outside of antenatal care clinics. The current
randomized controlled trial seeks to increase midlevel HCPs’ capacity, specifically nurses, who are often the first point
of contact in this setting, to identify women presenting at health clinics with experiences of IPV and to assist these
women with health risk mitigation. Specific outcomes include changes in past-year IPV (physical and/or sexual),
reproductive coercion, safety planning, use of community resources, and quality of life.
Methods/Design: Forty-two public health clinics in Mexico City were randomized to treatment or control clinics.
Nurses meeting eligibility criteria in treatment groups received an intensive training on screening for IPV, providing
supportive referrals, and assessing for health and safety risks. Nurses meeting eligibility criteria at control clinics received
the standard of care which included a one-day training focused on sensitizing staff to IPV as a health issue and referral
cards to give to women. Women were screened for eligibility (currently experiencing abuse in a heterosexual
relationship, 18-44 years of age, non-pregnant or in first trimester) by research assistants in private areas of waiting
rooms in health clinics. Consenting women completed a baseline survey and received the study protocol for that clinic.
In treatment clinics, women received the nurse delivered session at baseline and received a follow-up counseling
session after three months. Surveys are conducted at baseline, three months, and fifteen months from baseline.
Discussion: This study will provide important insight into whether a nurse-delivered program can assist women
currently experiencing abuse in a Latin American context. Findings can be used to inform IPV programs and policies in
Mexico City’s public health clinics.
Trial registration: NCT01661504
Keywords: Intimate partner violence, Violence against women, Randomized controlled trial, Screening, Counseling,
Mexico* Correspondence: jhumka.gupta@yale.edu
1Chronic Disease Epidemiology and Social and Behavioral Sciences, Yale
School of Public Health, New Haven, CT, USA
2Center for Interdisciplinary Research on AIDS, Yale School of Public Health,
New Haven, CT, USA
Full list of author information is available at the end of the article
© 2014 Falb et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Falb et al. BMC Public Health 2014, 14:772 Page 2 of 10
http://www.biomedcentral.com/1471-2458/14/772Background
Intimate partner violence (IPV) against women is a critical
health, human rights, and development concern, with glo-
bal estimates indicating that approximately one in three
women have reported such violence at some point in their
life [1]. Research has documented a range of negative
health effects from IPV, including poor mental health, un-
wanted pregnancies, reproductive coercion, and vulner-
abilities to HIV and sexually transmitted infections [2-7].
Within Mexico, approximately 25%-40% of women who
receive health sector services have reported violence
from their partners at some point in their life [8-10].
These lifetime IPV figures are comparable to other coun-
tries in Latin America and the Caribbean [11], and under-
score the importance of interventions in health care
settings. These approaches are critical as women experien-
cing IPV have been shown to disproportionately utilize
health care services [12], and providers may be in a unique
opportunity to intervene as they are among the few out-
side contacts a woman may have exposure to.
Despite the potential importance of health care provider
(HCP)-delivered IPV interventions and in particular, HCP
IPV screening programs, such approaches remain contro-
versial [13,14]. Much of the debate surrounding the screen-
ing of women for IPV by HCPs is due to mixed evidence
regarding the effectiveness of such approaches in reducing
IPV and improving health outcomes [15,16]. Moreover,
IPV screening by HCPs is not universally recommended
by professional health organizations [17]. However, it re-
mains unclear if the screening alone is an ineffective ap-
proach for addressing IPV or if HCPs do not fully adhere
to screening protocols. Lack of fidelity towards consistent
screening has been noted in systematic reviews due to a
variety of barriers perceived by HCPs [18]. In addition, as
studies evaluating screening for IPV involve vulnerable
populations of abused women, there may be high levels
of attrition [15], which may vary differentially by sever-
ity of IPV victimization and thus limit extrapolation of
findings. However, the evidence-base is growing to suggest
that comprehensive and systems-approaches to identifying
and counseling women experiencing IPV in health set-
tings is an effective strategy [19-21] to address both IPV
victimization and related health concerns.
Thus, rigorous evaluations, including randomized con-
trolled trials, of these combined and integrated HCP ap-
proaches are needed [17]. In particular, there is limited
evidence of their utility in Latin American countries, such
as Mexico, including attention to the potential mitigation
of broader health outcomes that are consistently associ-
ated with IPV, such as quality of life. One key health out-
come that may also be reduced with integrated screening
and counseling programs is reproductive coercion, which
may involve birth control sabotage or other pressure to
become pregnant [22,23]. In addition, while one pilotstudy conducted in Peru documented increases in safety
planning behaviors among abused pregnant women
who were screened for violence and received a counseling-
based empowerment intervention, uncertainty exists
regarding the effectiveness of safety planning or related
counseling approaches in low and middle income coun-
tries in clinics that do not focus solely on antenatal care
[24]. The examination of such broader short and long-
term health outcomes within the context of HCP deliv-
ered IPV interventions has been increasingly highlighted
as an important area of intervention research [16,25].
Evaluations of the efficacy of these HCP responses to
IPV are particularly needed within Mexico City, as the
health system’s response to IPV has been fragmented at
best. Briefly, Mexico City’s Ministry of Health (MoH) began
implementing a domestic violence program in 2006. This
program focused primarily on training health staff at hos-
pitals on violence prevention and referral, in accordance
with their internal protocol regarding IPV [26]. The IPV
program run by the MoH operates only within select hos-
pitals (12 out of 31); the program has staff specifically
assigned to offer psychological services to victims of IPV.
However, despite interest in expansion and efforts by or-
ganizations in the region to build public sector capacity to
address IPV, the program has not expanded due to limited
resources [27].
Additional challenges of the health sector response to
IPV were noted in the planning phase of the study after
in-depth discussions with the MoH and nurses at clinics.
First, HCPs, hereafter nurses, at health clinics have lim-
ited to no information about where to refer IPV cases
screened at the health clinics. Furthermore, nurses were
given a self-efficacy test and knowledge test related to IPV
as part of piloting the intervention and results showed
that only 45% of nurses (n = 187) were prepared to make
appropriate referrals for women experiencing IPV. Similar
challenges regarding skills, referral systems and general
knowledge of IPV have also been noted in other health
sector responses in low and middle income countries
[28,29]. In addition, despite efforts to address IPV [30],
there have been no trials in this context to assess effective-
ness of health sector interventions in Mexico City. This is
in contrast to the recent improvement in Mexican legisla-
tion which recognizes the right of women to live free from
violence, and asks for improvements in the provision of
services to the population [31].
To address these gaps in knowledge, we are conduct-
ing the currently described randomized controlled trial
to assess the efficacy of a comprehensive HCP delivered
intervention in Mexico City. The primary objective of
the study is to increase nurses’ capacity and self-efficacy to
identify IPV and assist women with risk mitigation.
Through this objective, nurses will be equipped to provide
counseling and information for women experiencing IPV,
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safety plans to reduce risk of severe violence, and to miti-
gate any adverse health risks. The trial outcomes are to:
(1) assess the efficacy of an enhanced nurse-delivered
screening and counseling program on the primary outcome
past year IPV, including severe IPV (sexual or physical) and
injuries from such IPV [32]; and secondary outcomes (b)
reproductive coercion [23] (c) use of community-based re-
sources and safety planning [33]; and (d) quality of life
and mental health [34]; versus minimum standard of care;
(2) to qualitatively examine which programmatic compo-
nents may serve as mechanisms for observed quantitative
changes stated in the outcomes; and (3) to synthesize
study findings and (a) create recommendations for clinic-
based intervention programs to address IPV in low and
middle income countries and (b) disseminate information
as reports, presentation, and peer-reviewed publications.
Methods/Design
Study design
Our study utilizes a cluster-randomized controlled trial
design and will take place between 2012 - 2015. Briefly,
42 public health clinics (first level of care facilities) were
randomized to either the treatment or control conditions
and women are to be assessed for information at base-
line, time 2 (3 month follow-up), and time 3 (15 month
follow-up). Further details are described below.
Study setting
Mexico City, the capital and most populous urban center
of Mexico, provides the study setting in which our research
will occur. In this megacity, almost half of the population
is uninsured (approximately 3,859,963 residents) [35]. The
uninsured population receives health care, through the fed-
eral health care program, Seguro Popular, at MoH clinics
in Mexico City, this public insurance scheme aims at pro-
viding universal health care; a right recognized in the
Mexican constitution of 1983 [36].
The MoH health system in Mexico City comprises 206
health clinics and 31 hospitals. The 206 MoH clinics are
classified into Type I, Type II and Type III based on level
of care. Clinics classified as Type III are large clinics that
offer a broader array of services than Type I or II clinics.
For instance Type III clinics offer laboratory tests. Clinics
classified as Type I and II, are community clinics with 1 or
2 doctors and about 2 nurses; their focus is on community
outreach and immunizations with Type I being the smal-
lest level of community health center. Type III clinics were
selected to participate in the study after conversations
with the MoH because of their lack of IPV services and
larger patient volume compared to Type I and Type II.
These Type III clinics, chiefly located in low and middle
income neighborhoods, serve primarily a low income
population, and are thus eligible for the Seguro Popular.The number of women served by these health clinics var-
ies greatly from borough to borough. Over 2,336,000 resi-
dents use the services of the MoH health clinics and
hospitals annually [37].
At these Type III primary care clinics, the first points
of contact for patients are nurses. The flow of patients at
these clinics is as follows: patients line up early in the
morning in order to get an appointment on a first come
first served basis; although the MoH is currently imple-
menting an appointment system that will reduce waiting
times for patients. Nurses take somatometry measure-
ments on all patients before they are seen by the doctors.
Social workers do not have contact with every patient un-
less they are specifically needed in instances if patients
need a referral to a hospital or to a different health clinic.
Out of the 60 Type III health clinics, one was excluded
from potential recruitment because it was located in the
borough of Milpa Alta; a remote and rural location with
limited access to community resources and a small popu-
lace (<2% of Mexico City’s population). Two additional
clinics were excluded to reduce contamination. These hos-
pitals were located less than three blocks from hospitals
and some hospitals also had violence against women
programs.
Randomization, sample size, and power analysis
Approximately 900 women from 42 health clinics were
calculated to be sufficient sample size in order to achieve
80% power to detect a 15% difference in IPV frequency
between treatment versus control arms at the α < 0.05
statistical significance level. A conservative intraclass cor-
relation of 0.07 was assumed for clustering at the clinic
level. This total sample size takes into account an attrition
rate of 45%. The study proposal has budgeted for tracking
participants that are relatively more difficult to track in
order to reduce attrition.
Health clinics were first stratified by city zone (e.g. Center,
North, East, West, South). Of the 57 health clinics that
met inclusion criteria, 42 were randomly selected and ran-
domized to treatment or control conditions, based on
sample size calculations. To select the 42 health centers,
all centers were assigned random numbers in Excel and
sorted from smallest to largest; health centers were se-
lected based on city zone and in order of their random
number. Randomization was completed in STATA.
Study population, recruitment, and retention
Women were eligible to participate in the study if they
were between the ages of 18-44 years, currently in a het-
erosexual relationship with a male partner, responded in
affirmative to past year sexual or physical IPV, and was
not pregnant or pregnant in their first trimester. Study ex-
clusion criteria included cognitive impairment (e.g. slurred
speech), seeking treatment for life threatening emergency
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assistants approached women in the waiting rooms of par-
ticipating clinics, verified eligibility for the study, and
asked women to take an assessment screening that con-
tained items from an abuse assessment screen that is
widely used by International Planned Parenthood Feder-
ation/Western Hemisphere Region (IPPF/WHR) in Latin
American and Caribbean countries and has been previ-
ously used in studies occurring in Mexico City [38-40].
Based on feedback from piloting the assessment, the final
tool consisted of eleven questions in order to build rap-
port between the research assistant and participant. The
first nine questions were in regards to the woman’s health
and relationship with her partner, including emotional
abuse, as directly asking about physical or sexual IPV at
the very beginning of the assessment was rendered as too
sensitive during our piloting phase. Based on feedback
from focus groups carried out with IPV survivors at a
community domestic violence agency, concrete examples
of physical and sexual IPV were included in the questions
(see Figure 1). If a woman answered at least one affirma-
tive response to the validated screening items on physical
and sexual IPV contained in the assessment, they wereFigure 1 Abuse assessment screening.invited to participate in the study; those interested com-
pleted written and/or verbal informed consent. Both the
assessment and the informed consent process took place
within a private area of the clinic.
At baseline data collection, women were asked for
their contact information, including the names of three
other people in case the woman could not be reached
for follow-up appointments. Research assistants called
every number provided by the participant to verify that
the phone numbers were functional. Participants re-
ceived a call on average 3 days after they completed the
baseline to verify contact information. All participants
agreed that it was okay to call them and research assis-
tants were trained to ask if it was a safe time to talk and
did not mention violence or the study if another person
answered the phone.
All women received monthly follow-up phone calls to
remind them of 3 month and 15 month follow-up appoint-
ments. At all times their disclosure of IPV remained confi-
dential and the purpose of the study was not be shared
with anyone. Upon conclusion of the surveys and counsel-
ing at baseline, all women received a snack for their time.
At the three month follow-up they received a gift card for
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will receive $20 USD. The amounts and type of compensa-
tion were determined based on consultation with Mexfam
(Mexican Foundation for Family Planning) and the MoH,
as well as responses from a short survey given to women
at health clinics during our piloting phase regarding their
preferred mode of compensation (e.g. phone credit, food,
gift card, etc).
Data were collected through a computer-assisted sur-
vey which has been shown to improve response rates to
sensitive behaviors [41]. Participants completed the sur-
vey in a private space in the clinic and were able to listen
to the questions in Spanish through headphones and an-
swer on the keyboard. Research assistants were available
during this period in case the participant had any ques-
tions. Given that clinics were randomized and not indi-
viduals, research assistants were not blinded to whether
they were in a treatment or control clinic.
Intervention description
Women who participated in the study at treatment clinics
received the following intervention: (1) integrated IPV and
health screening; (2) supportive care; (3) safety planning
and harm reduction counseling; (4) supportive referrals;
and (5) booster counseling sessions at three months post
baseline. The majority of materials utilized for the inter-
vention were adapted from existing IPPF/WHR materials
used in other Latin American and Caribbean contexts and
were adapted to the characteristics of Mexico City [38]. A
referral directory was also created with the contact infor-
mation of local community agencies that provide services
to IPV victims. During the development phase of the re-
ferral directory, IPV staff at the MoH suggested that only
community agencies providing free services be included.
All community agencies listed in the directory were visited
by research staff and addresses and phone numbers were
verified. Furthermore, for each community agency, re-
search staff obtained the name of a specific contact person
to include in the referral directory. Contact names were
included in the referral directory based on pilot focus
group research with IPV survivors enrolled at a commu-
nity agency. Pilot work revealed that women felt more
comfortable asking for services if there was a specific per-
son to contact at an agency; and that only having the
name of an agency was a deterrent.
Of the agencies, two programs were highlighted: (1)
SEPAVIGE, the MoH IPV program, (Gender based
Violence Special Services) and UAVIF (Family Violence
Prevention and Care Unit). There are approximately 14
SEPAVIGE units located primarily within hospitals. Key
services include free psychological treatment and group
therapy to IPV victims. UAVIF is associated with the
Ministry of Social Development and it consists of 16
units in each district of Mexico City. Each unit offerslegal and psychological services. They are also in charge of
identifying women eligible for an IPV conditional cash
transfer program. The referral directory was handed out to
nurses during the training Details are presented in Table 1.
Nurses from all 42 health clinics were invited to partici-
pate in the training based on the following criteria: morn-
ing shift nurses (due to the walk-in basis of appointments
and afternoon shifts not occurring at all clinics) and not a
field nurse (due to their limited time at the health clinics).
A total of 197 nurses (approximately 8% male nurses and
45% in treatment clinics) received the training. 147 nurses
are actively participating in the study (49% in treatment
clinics) (26% staff dropped out primarily due to staff turn-
over at clinics). On average, 4 nurses were trained at each
health clinic. Nurses in the intervention group received a
3 day training that covered all the topics of the interven-
tion and then nurses received up to 3 visits by research
staff to practice delivering the intervention through role –
playing exercises individually and in the clinics. In-depth
training was needed as nurses did not feel very comfort-
able talking about IPV and several rounds of role playing
exercises were needed for nurses to gain confidence. Role-
playing exercises with research staff were chosen as it
preserved rapport between nurses and the research team
as well as increased confidentiality of nurses requiring add-
itional training. All training activities were conducted by
the research team, IPPF training consultants, and invited
guests from local organizations and government offices
who specialize in this area. Specific topics in the training in-
cluded an introduction to IPV, health consequences of IPV,
legal considerations in Mexico City, methods to screen for
violence and assess for health implications such as repro-
ductive coercion, safety and ethical considerations, referral
methods and linkages to other organizations in the com-
munity. An educational video modeling the counseling ses-
sions was also developed by the study team for the training
of treatment nurses. This video was shown and discussed
during research assistant visits to the health clinics as part
of the training.
Women in the control clinics were given a referral card
containing general information on IPV and a list of re-
sources, which was consistent with the current goal for
standard of care in the Mexico City MoH. The referral card
is the size of a business-card so that it may easily be hidden
from male partners, and is widely used in other IPV screen-
ing programs [42]. Staff in control clinics received a one
day training that focused mainly on sensitizing nurses and
training them on using the abuse assessment. Control clinic
staff will receive the intervention training upon completion
of the study.
Ethics
Conducting research with women who have recently ex-
perienced violence represents a number of safety concerns
Table 1 Intervention components
Intervention component Description
Integrated IPV and health
screening
Women will be screened for IPV including emotional, physical, and sexual violence, as part of a general health
assesment.
Supportive care Nurses will be trained to provide non-judgmental and empathetic counseling, .
Safety planning and harm
reduction counseling
Nurses will discuss safety planning measures with women, including escape routes or places of refuge, packing and
storing a bag with important belongings, memorizing phone numbers, talking to children about what to do in cases
of violence, and staying away from rooms with weapons. Harm reduction counseling will include the partners’ use of
alcohol and illicit drugs, how to remove weapons, options for protecting reproductive health, such as protecting
against unplanned pregnancy, sexually transmitted infections, and other individual-specific health risks.
Supportive referrals Women will be counseled about local IPV and sexual assault resources according to their specific needs. Access and
utilization will be facilitated by contacting programs together or by offering the woman step-by-step directions.
Business-sized referral cards which contain contact information for local resources, will be given to all women.
Booster counseling sessions
at 3 months
Components of above screening, referral, safety planning and harm reduction will be reviewed and redelivered to
program participants. Sessions will occur in clinic and information will be recorded in patient charts.
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Organization standards for conducting research on do-
mestic violence [44] and were taken into account during
study preparations. First, all women will provide informed
consent which stresses the voluntary nature of the study,
the ability to skip questions as necessary, confidentiality,
and outlines potential risks and benefits of participation.
At the end of the survey, health care providers explain
available resources for emotional support and provide a
list of resources. Second, the study was designed so as not
to reveal to the partner the purpose of the study or the
woman’s participation in the study. At all times a woman’s
disclosure of IPV remained confidential, including the
three friends or family members she listed in case she
could not be contacted at follow-up. During follow-up
calls, the specific purpose of the study was not given; ra-
ther, it was referred to as a study on “women’s health and
families”. All research staff were trained by senior study
personnel on study ethics. Regular de-briefings, including
recommendations for self-care, occurred with research as-
sistants to reduce vicarious trauma among staff. Research
staff and nurses participating in the study were en-
couraged to report any emotional distress, including if
they were struggling with experiences of victimization in
their own lives, to principal investigators. Study proce-
dures have been approved by the Yale School of Public
Health (Protocol # 1202009793), Innovations for Poverty
Action (Protocol # 555.23May-001), and National Institute
of Public Health (Mexico) (Project #1089) institutional
review boards.
Quantitative assessments & analytic plan
Our primary outcome is past-year IPV [32] and our sec-
ondary outcomes include past-year reproductive coer-
cion [7,23], use of community-based resources [33], safety
planning measures [33], and quality of life [34]. Descrip-
tive statistics will be used to assess achievement of Aim 1.
For the remaining aims, the follow analyses plans will beundertaken: (1) assess if randomization of health clinics
was successful by examining if there are statistically sig-
nificant differences between women’s demographics, by
treatment arm, through chi-square or t-tests; (2) assess for
differential loss to follow up by demographics and baseline
IPV severity; (3) assess if IPV and secondary outcomes (re-
productive coercion, safety planning, use of community
resources, quality of life) differed at baseline, by treatment
arm; and (4) conduct multilevel analyses of the effect of
the intervention on outcomes utilizing appropriate models
that will account for potential clustering for repeat mea-
sures, time, and at the clinic level. We will subsequently
estimate adjusted models if any demographics significantly
varied at baseline. Analyses will first be undertaken using
the intent-to-treat approach. Following this, a per protocol
analysis will be undertaken to determine whether effect-
iveness varied by adherence (i.e. attending the three
month booster counseling session) and potentially nurse
adherence.
Qualitative assessments & analytic plan
During endline data collection, research assistants will con-
duct 45 qualitative interviews with female participants to
provide insight into observed quantitative results. In-depth
interviews will consist of questions regarding perceptions of
IPV, safety planning behaviors, reproductive autonomy, and
quality of life. Underscoring all questions will be the
woman’s perception of how, if at all, participating in the
intervention created or affected these changes. Additionally,
fifteen interviews were conducted with nurses at treatment
clinics to understand their experiences with the HCP deliv-
ered approach between the three month follow-up period
and the final endline at fifteen months. Interviews will last
no longer than one hour and be conducted in Spanish.
Upon transcription of audio recordings, interviews will be
translated into English. All interviews will be coded using
inductive thematic analysis [45] through which emerging
themes will be discussed with principal investigators.
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Throughout the study period, a process evaluation is
conducted, consisting of three key activities: (1) pre-post
tests of the nurse training; (2) fidelity assessments with
mock clients; and (3) exit interviews with women par-
ticipating in the study. First, during the training of
nurses, we conducted a pre-post test before and after
the training to assess the change in knowledge, attitudes,
and skills among nurses in regards to screening and re-
ferral for IPV. In addition to assessing nurses’ skills for ad-
dressing IPV, these pre-posttests were undertaken due to
previously noted challenges that may hinder effective in-
terventions, such as health care providers’ victim-blaming
attitudes and misconceptions of IPV [28]. Throughout the
study, nurses are asked to fill out the short survey at three
month intervals to assess any changes, although test-retest
bias is a limitation of this process evaluation method.
Second, anonymous mock clients are used in order to
assess nurses’ adherence to protocols and to serve as an
opportunity to provide feedback during the training phase.
Existing literature has also underscored the lack of feed-
back given to health care providers as a reason for infidel-
ity to screening protocols [18]. Therefore, after completing
the training, all intervention nurses are visited by trained
research staff. The staff member screens positive for IPV,
and goes through the clinic visit, including screening,
referral, and counseling following a scripted scenario. Fol-
lowing the health visit, the staff member completes a fidel-
ity checklist to determine areas in which the nurse is
exceeding expectations and areas in which the nurse needs
improvement. All nurses are informed that they will be vis-
ited by a mock client and that all mock clients will adhere
to the script used in the training. No health nurse receives
more than two mock client visits throughout the study
period. Feedback was given during on-site training prior to
the launch of the baseline; subsequent visits were used for
fidelity monitoring only. Nurses in the control group also
received one visit from the mock client, but feedback will
only center on standard of care, rather than comprehensive
screening and counseling women. Fidelity checklists from
these mock clients do not contain identifying information
and were entered into a secure database upon completion.
Tape recording counseling sessions were also considered
as a method of assessing fidelity. However, due to safety
concerns for the women, mock clients were chosen as the
more appropriate method to assess intervention fidelity.
The final activity to monitor fidelity was exit interviews
with women in both treatment and control clinics. Women
who were participating in the study in treatment clinics
were randomly selected by research staff in the clinic after
they had received the intervention, based on selection of
questionnaire identification numbers. Exit interviews are
designed to last between 5-10 minutes where all women
were asked to provide an additional written informedconsent prior to completing the survey. All women in the
intervention and control groups were eligible to participate
in the exit interviews.
Costing analysis
A costing analysis is also included in the study protocol.
Trained research assistants have been identifying human,
financial, physical, and time resources required for the
HCP delivered program throughout the study. Data has
been collected and categorized by research-related costs or
operational costs in order to calculate the monetary value
of resources needed to conduct the intervention. The costs
and effectiveness of this approach will be compared be-
tween treatment versus control groups and will mirror
methodology from a previous cost-effectiveness analysis of
an IPV intervention [46]. This costing exercise will provide
insight into the scalability of the intervention and eco-
nomic impacts of broader policy recommendations.
Discussion
This study seeks to train and improve nurses’ capacities
to deliver an intervention for women currently experien-
cing IPV that present at health clinics in Mexico City. If
found efficacious, this study may have an important in-
fluence on programming and policy for the health sector
responses in city-based clinics serving low-income women
in the region. Findings may also contribute to the evidence-
base for comprehensive prevention strategies to reduce IPV
and to respond to the needs of survivors. This interven-
tion may be an effective health-sector tool to reduce IPV
and mitigate negative effects, in addition to many other
approaches including changes in the legal system or other
social change approaches that focus on gender equality
and the engagement of men to reduce violence [47-49].
Despite the strong study design to assess the efficacy of
the HCP delivered intervention on outcomes, limitations
and potential problems have been considered. As with
other randomized controlled trials, participant drop-out
and differential attrition is a concern [19]. To address po-
tential problems, we have added an exclusionary criterion
that women do not plan on relocating within the study
period. At the time of enrollment, we also verify contact
information for the woman and obtain information for
three additional contacts that would know how to get in
touch with her. In the analysis plan, we will assess for dif-
ferential attrition and potentially adjust final models for
variables that may have statistically differed between treat-
ment arms. Other approaches may also be used to handle
missing data, including multiple imputation, which has
been used in other studies examining IPV screening effect-
iveness [15].
In addition, staff at referral community agencies that
are aware of and engaged with the study may also turn-
over, which may have a bearing on the quality of service
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responses to IPV, linkages to community agencies may
be a critical component of success [29]. While there are
agencies for referral in Mexico City, including UAVIF,
the quality of services received at referral community
agencies remains unclear as it is outside the scope of the
current study. In addition, there may be challenges in
the capacity of referral agencies to respond to significant
increases in referrals. Nonetheless, we will be able to as-
sess utilization of agency services through the quantita-
tive assessments with participants and gain insight into
experiences through qualitative interviews. Within the
clinics themselves, pilot work revealed the lack of private
spaces as a physical challenge of conducting the survey
and administering the HCP delivered intervention. While
the study team has worked with clinic staff to identify pri-
vate spaces to maintain confidentiality of participants,
considerations of space must be addressed if the interven-
tion were to be scaled up. Similar challenges have been
noted elsewhere [28,29] among health clinic interventions
in low and middle income countries.
Another potential limitations that may affect our abil-
ity to see changes in IPV, that result from the interven-
tion, is the limited follow-up time of the intervention.
IPV, as noted by others [50], is a complex issue that may
often require many attempts to leave an abusive partner.
Thus, changes in IPV may be difficult to discern given the
twelve-month follow-up after the second counseling ses-
sion. However, our selection of secondary outcomes in-
cluding changes in use of community resources and safety
planning behaviors will allow us to see potential changes
that may occur on the pathway to eventually leaving a
partner. Nonetheless, statistically significant changes in
other secondary outcomes, such as quality of life, may also
be difficult to discern in the short follow-up period. For
instance, housing relocations, childcare considerations,
etc. may also have a negative influence on quantitative
measures of quality of life as a result of leaving an abusive
partner. However, qualitative interviews among women at
the follow-up period will provide a meaningful narrative
of women’s intervention-related experiences and attempts
to leave their abusive partner. The mixed methods ap-
proach to understanding intervention impacts may be im-
portant, particularly for quality of life, as previous studies
have documented null associations between quality of life
and IPV screening [51].
In addition, due to logistical constraints, we could not
train all personnel at health clinics, thus this is not a
system-wide intervention. Therefore, we are limited con-
cerning inferences we can make regarding institutional
changes necessary for comprehensive health sector re-
sponses to IPV. MoH clinics were not able to send all
nurses to the training even when trainings on different
dates were held, nor were we able to train all front-linestaff at the clinics. Consequently, we focused our efforts
on recruiting non-field based nurses who have the high-
est probability of seeing the most patients in the clinic
and were on morning shifts. Nonetheless, we will be able
to test the potential efficacy of an HCP delivered program
on IPV and related outcomes in an urban, middle-income
country health system setting. If proven to be a feasible
approach, future studies and monitoring efforts could be
built into scale-up of activities among all nurses at health
clinics. This first step is particularly feasible given the
MoH’s investment in IPV programs. In addition, our on-
going process evaluations and training to nurses will pro-
vide a supportive environment to increase their efficacy to
address IPV.
In summary, this trial will seek to train and increase cap-
acity of nurses in Mexico City to identify and respond to
IPV and generate evidence if such an approach is effective
in reducing IPV and mitigation of related health concerns.
If found to be efficacious, the study may offer important
contributions and insights regarding how to increase the
capacity of the health sector to respond to survivors of IPV
in Mexico City. Ultimately, the results of this trial will con-
tribute to global knowledge on the key role of HCPs in ad-
dressing IPV.
Trial status
Study recruitment is currently underway at the time of
initial manuscript submission. Upon resubmission, the
baseline and three-month follow-up surveys have been
completed.
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